BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29720474)

  • 1. Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.
    Johnstone CN; Pattison AD; Gorringe KL; Harrison PF; Powell DR; Lock P; Baloyan D; Ernst M; Stewart AG; Beilharz TH; Anderson RL
    Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29720474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF13 promotes metastasis of triple-negative breast cancer.
    Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH
    Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
    Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
    Schech A; Kazi A; Yu S; Shah P; Sabnis G
    Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
    Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
    Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.
    Kong B; Lv ZD; Wang Y; Jin LY; Ding L; Yang ZC
    Int J Clin Exp Pathol; 2015; 8(9):11076-83. PubMed ID: 26617826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
    Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
    Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.
    Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D
    Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
    Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
    Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
    Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
    Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.